Mamedica, the UK’s leading provider of cannabis-based prescription medicines, has secured £4.5 million in new funding, with US venture capital firm Casa Verde leading the round. This landmark investment underscores strong confidence in the UK’s evolving cannabis sector, which analysts expect to reach £1 billion in annual sales by 2028. For investors, the deal presents a unique opportunity to participate in a rapidly expanding segment of the healthcare industry.
A rapidly expanding healthcare platform
Founded in 2022, Mamedica has grown quickly by leveraging a digital-first healthcare model. Patients with chronic pain, anxiety, ADHD, depression, and other neurological conditions can book specialist consultations remotely and, if approved, receive prescriptions for cannabis-based medicines delivered securely to their homes the next day.
This streamlined model has not only lowered barriers to access but has also positioned Mamedica as a trusted and scalable provider. Since launch, the company has treated more than 10,000 patients, with approximately 7,500 under active care. Growth metrics are striking: a 1,250% patient expansion in 2023, followed by a 154% increase in 2024, with management forecasting that patient numbers will double annually for the foreseeable future.
Such figures reflect both rising consumer acceptance of cannabis-based treatments and the strong operational foundations Mamedica has built in just three years.
Scaling operations with new capital
The newly raised £4.5 million will be allocated across four strategic areas designed to consolidate Mamedica’s market leadership:
- Supply chain optimisation: Enhancing in-house logistics to ensure continuity of care and reduce reliance on third parties.
- Clinical network expansion: Increasing the pool of qualified clinicians to meet growing patient demand.
- Digital healthcare advancements: Investing in automation, compliance tools, and patient interface improvements.
- Education and awareness: Supporting the integration of medical cannabis into mainstream healthcare by training professionals and informing patients.
Together, these initiatives are expected to extend Mamedica’s reach to as many as 100,000 patients in the coming years, making it one of the most influential players in European cannabis-based medicine.
Backing from a proven cannabis investor
Casa Verde, founded in Los Angeles, has built a reputation as one of the most influential venture capital firms in the cannabis space. Its portfolio includes Dutchie, Metrc, and Leaflink, three companies that have shaped the infrastructure of the US cannabis industry.
By leading the Mamedica round, Casa Verde is signalling strong confidence in the UK’s medical cannabis framework and in the ability of Mamedica’s model to replicate the success of its US peers. For investors, this represents both validation of the company’s trajectory and assurance that Mamedica is backed by seasoned industry specialists.
The UK cannabis market outlook
While the UK is still at an earlier stage compared to North America, medical cannabis adoption is accelerating. Since the legalisation of cannabis-based prescription medicines in 2018, regulatory clarity and patient demand have steadily increased. By 2028, forecasts suggest the market will generate £1 billion annually, driven by greater clinical acceptance, patient education, and more efficient healthcare delivery models.
Mamedica’s growth trajectory mirrors these trends. With its digital-first approach, emphasis on patient care, and capacity to scale, the company is positioned to capture significant market share as the UK shifts toward wider adoption of cannabis-based healthcare solutions.
Why this matters for investors
For investors focused on the cannabis sector, Mamedica’s latest funding round offers several compelling takeaways:
- Strong growth trajectory: Consistent triple-digit annual patient growth since inception.
- Market timing: Expansion aligns with a UK market projected to hit £1bn by 2028.
- Experienced backers: Casa Verde brings proven expertise and network advantages.
- Scalable model: Digital-first infrastructure reduces barriers to nationwide expansion.
As the medical cannabis industry matures in the UK, companies with strong regulatory compliance, established patient trust, and operational efficiency will be best positioned to deliver long-term returns. With fresh funding secured and a rapidly expanding patient base, Mamedica stands out as a frontrunner in this evolving sector.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
